J Dig Cancer Res.  2023 Aug;11(2):85-92. 10.52927/jdcr.2023.11.2.85.

Noninvasive Testing for Colorectal Cancer Screening: Where Are We Now?

• Chun J
• Kim JH
• Youn YH
• Park H

• KMID: 2545356
• DOI: http://doi.org/10.52927/jdcr.2023.11.2.85

Abstract

Colorectal cancer (CRC) is one of the most prevalent cancers and is the leading cause of cancerrelated mortality worldwide. Based on the current screening guidelines by the American Cancer Society and Korean multi-society expert committee, CRC screening is recommended in asymptomatic adults starting at the age of 45 years. Fecal immunochemical test-based screening programs reduce the development of CRC and related mortality in the general population. However, this most popular CRC screening strategy demonstrates a crucial limitation due to modest diagnostic accuracy. Colonoscopy may be considered as an alternative primary method for CRC screening; however, its implementation can still be challenging due to concerns regarding invasiveness, low adherence, cost-effectiveness, and quality assurance. To overcome the limitations of current screening tests, innovative noninvasive tests for CRC screening have been developed with advances in molecular biology, genetics, epigenetics, and microbiomics for detecting CRC, which may enhance the approach to CRC screening and diagnosis in clinical practice in the near future. This review explores the emerging screening methods and discusses their potential for integration into current practice.

Keyword

Colorectal neoplasms; Genetics; Liquid biopsy; Mass screening